Document:

Exhibit 10.4

 

Joinder to Share Purchase Agreement

 

This Joinder Agreement
(this “Joinder Agreement”) is made as of the date written below by Glenrock Israel Ltd. (the “Joining
Party”) in accordance with Section 4.3 of that certain the Share Purchase Agreement dated September 27, 2011 (the “Investment
Agreement”) by and among Enzymotec Ltd. and investors named therein, as the same may be amended from time to time. Capitalized
terms used herein, but not defined, shall have the meaning ascribed to such terms in the Investment Agreement.

 

The Joining Party hereby
acknowledges, agrees and confirms that, by its execution of this Joinder Agreement, the Joining Party shall be deemed to be a party
to the Investment Agreement as of the date hereof and shall have all of the rights and obligations of an “Investor”
there under as if it had executed the Investment Agreement. The Joining Party hereby ratifies, as of the date hereof, and agrees
to be bound by, all of the terms, provisions and conditions contained in the Investment Agreement and any other document contemplated
thereby.

 

Subject
to the terms and conditions set forth in the Investment Agreement, upon execution hereof, the Company shall issue and allot to
the Joining Party, and the Joining Party shall purchase from the Company, 138 of the Company's Preferred B2 Shares, nominal
value NIS 0.01 each, at a price per Preferred B Share of US$ 363.30, and in consideration for an aggregate purchase price of US$
50,000, which will be transferred to the Company as follows: (i) 50% out of the aforesaid amount – upon signing of this
Joinder Agreement; and (ii) the remaining 50% out of the aforesaid amount – in accordance with the provisions of Section
1.3.2 of the Investment Agreement but in any event, not later than December 31, 2012.

 

IN WITNESS WHEREOF,
the undersigned has executed this Joinder Agreement as of the date written below.

 

Date: December 26th, 2011

 

	 	/s/ Leon Recanati
	 	Glenrock Israel Ltd.
	 	 
	 	By:	Leon Recanati
	 	Title:	Chairman and CEO

	 	Address:	85 Medinat Hayehudim St., Herzliya Pituach, Israel

 

Acknowledged and Agreed:

 

	/s/ Oren Bryan	 
	Enzymotec Ltd.	 
	 	 
	By: Oren Bryan	 
	 	 
	Title: CFO	 
	 	 
	Date: December 29, 2011Exhibit 10.5

 

Joinder to Share Purchase Agreement

 

This Joinder Agreement
(this “Joinder Agreement”) is made as of the date written below by Israel Secondary Fund (ISR) L.P. (the
“Joining Party”) in accordance with Sections 4.3 and 4.4 of that certain the Share Purchase Agreement dated
September 27, 2011 (the “Investment Agreement”) by and among Enzymotec Ltd. and investors named therein, as
the same may be amended from time to time. Capitalized terms used herein, but not defined, shall have the meaning ascribed to such
terms in the Investment Agreement.

 

Whereas,
the Company confirmed to the Joining Party that, pursuant to Section 4.2.1(vi) of Investment Agreement, the Company's has obtained
the irrevocable waiver by all applicable shareholders of the Company and by any other applicable third party, with respect to any
preemptive rights, rights of first refusal, anti-dilution rights, or similar rights such shareholder or third party may have in
connection with the joining of the Joining Party to the Investment Agreement and the issuance to the Joining Party of the shares,
the Warrants and the shares underlying the Warrant, all as set forth in the Investment Agreement and in this Joinder Agreement.

 

Now,
Therefore, the Joining Party hereby acknowledges,
agrees and confirms that, by its execution of this Joinder Agreement, the Joining Party shall be deemed to be a party to the Investment
Agreement as of the date hereof and shall have all of the rights and obligations of an “Investor” there under as if
it had executed the Investment Agreement. The Joining Party hereby ratifies, as of the date hereof, and agrees to be bound by,
all of the terms, provisions and conditions contained in the Investment Agreement and any other document contemplated thereby.

 

Subject to the terms
and conditions set forth in the Investment Agreement, the Company shall:

 

		(1)	issue and allot to the Joining Party, on the dates set forth in this
section below, 660 of the Company's Preferred B2 Shares, nominal value NIS 0.01 each (the "Shares"), at
a price per Preferred B Share of US$ 363.30, and in consideration for an aggregate purchase price of US$ 240,000 (the "Investment
Amount"), which will be transferred to the Company as follows: (i) 50% out of the Investment Amount, payable in consideration
for 330 Shares to be issued on the date hereof – upon signing of this Joinder Agreement, subject to the fulfillment of the
terms and conditions set forth in Section 4.4 of the Investment Agreement; and (ii) the remaining 50% out of the Investment Amount
(the "Additional Amount"), payable in consideration for the remaining 330 Shares to be issued on the date the
Additional Amount is actually transferred to the Company – in accordance with the provisions of Section 1.3.2 of the Investment
Agreement but in any event, not later than December 31, 2012. For the avoidance of doubt,
in the event that the Joining Party does not transfer to the Company (on such dates set forth in Section 1.3.2 of the Investment
Agreement) the Additional Amount in full, then the number of Shares actually issued on such dates may be correspondingly reduced
to reflect the actual portion out of the Additional Amount transferred to the Company. 

 

		(2)	Issue to the Joining Party, on the date hereof, a Warrant (as defined in the SPA) to purchase 66
Shares, at a price per Share of US$ 363.30. Upon receipt by the Company of any portion of the Additional Amount, it shall issue
to the Joining Party an additional Warrant covering 20% of the additional portion of the Additional Amount so transferred, in accordance
with Sections 3.1 and 4.4.6 of the Investment Agreement (up to Warrants to purchase a maximum of additional 66 Shares).

 

[Signature Page to
Follow]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the undersigned has executed this Joinder Agreement as of the date written below.

 

Date: December 29, 2011

 

	 	/s/ Shmuel Shilo        /s/ Dror Glass
	 	Israel Secondary Fund (ISR) L.P.
	 	 
	 	By:	Shmuel Shilo      Dror Glass
	 	Title:	Managing Partners

	 	Address:	14 Shenkar, Herzliya, Israel

 

Acknowledged and Agreed:

 

	/s/ Oren Bryan	 
	Enzymotec Ltd.	 
	 	 
	By: Oren Bryan	 
	 	 
	Title: CFO	 
	 	 
	Date: December 29, 2011Exhibit 10.6

 

Joinder to Share Purchase Agreement

 

This Joinder Agreement
(this “Joinder Agreement”) is made as of the date written below by Israel Secondary Investments (BVI) L.P.
(the “Joining Party”) in accordance with Sections 4.3 and 4.4 of that certain the Share Purchase Agreement dated
September 27, 2011 (the “Investment Agreement”) by and among Enzymotec Ltd. and investors named therein, as
the same may be amended from time to time. Capitalized terms used herein, but not defined, shall have the meaning ascribed to such
terms in the Investment Agreement.

 

Whereas,
the Company confirmed to the Joining Party that, pursuant to Section 4.2.1(vi) of Investment Agreement, the Company's has obtained
the irrevocable waiver by all applicable shareholders of the Company and by any other applicable third party, with respect to any
preemptive rights, rights of first refusal, anti-dilution rights, or similar rights such shareholder or third party may have in
connection with the joining of the Joining Party to the Investment Agreement and the issuance to the Joining Party of the shares,
the Warrants and the shares underlying the Warrant, all as set forth in the Investment Agreement and in this Joinder Agreement.

 

Now,
Therefore, the Joining Party hereby acknowledges,
agrees and confirms that, by its execution of this Joinder Agreement, the Joining Party shall be deemed to be a party to the Investment
Agreement as of the date hereof and shall have all of the rights and obligations of an “Investor” there under as if
it had executed the Investment Agreement. The Joining Party hereby ratifies, as of the date hereof, and agrees to be bound by,
all of the terms, provisions and conditions contained in the Investment Agreement and any other document contemplated thereby.

 

Subject to the terms
and conditions set forth in the Investment Agreement, the Company shall:

 

		(1)	issue and allot to the Joining Party, on the dates set forth in this
section below, 28 of the Company's Preferred B2 Shares, nominal value NIS 0.01 each (the "Shares"), at
a price per Preferred B Share of US$ 363.30, and in consideration for an aggregate purchase price of US$ 10,000 (the "Investment
Amount"), which will be transferred to the Company as follows: (i) 50% out of the Investment Amount, payable in consideration
for 14 Shares to be issued on the date hereof – upon signing of this Joinder Agreement, subject to the fulfillment of the
terms and conditions set forth in Section 4.4 of the Investment Agreement; and (ii) the remaining 50% out of the Investment Amount
(the "Additional Amount"), payable in consideration for the remaining 14 Shares to be issued on the date the Additional
Amount is actually transferred to the Company – in accordance with the provisions of Section 1.3.2 of the Investment Agreement
but in any event, not later than December 31, 2012. For the avoidance of doubt, in the event
that the Joining Party does not transfer to the Company (on such dates set forth in Section 1.3.2 of the Investment Agreement)
the Additional Amount in full, then the number of Shares actually issued on such dates may be correspondingly reduced to reflect
the actual portion out of the Additional Amount transferred to the Company. 

 

		(2)	Issue to the Joining Party, on the date hereof, a Warrant (as defined in the SPA) to purchase three
(3) Shares, at a price per Share of US$ 363.30. Upon receipt by the Company of any portion of the Additional Amount, it shall issue
to the Joining Party an additional Warrant covering 20% of the additional portion of the Additional Amount so transferred, in accordance
with Sections 3.1 and 4.4.6 of the Investment Agreement (up to Warrants to purchase a maximum of additional six (6) Shares).

  

[Signature Page to
Follow]

 

    	 

    	 

    

 

 

IN WITNESS WHEREOF,
the undersigned has executed this Joinder Agreement as of the date written below.

 

Date: December 29, 2011

 

	 	/s/ Shmuel Shilo        /s/
Dror Glass
	 	Israel Secondary Investments (BVI) L.P.
	 	 
	 	By:	Shmuel Shilo      Dror Glass
	 	Title:	Managing Partners 

	 	Address:	14 Shenkar, Herzliya, Israel

 

Acknowledged and Agreed:

 

	/s/ Oren Bryan	 
	Enzymotec Ltd.	 
	 	 
	By: Oren Bryan	 
	 	 
	Title: CFO	 
	 	 
	Date: December 29, 2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]